 |
Hanmi |
[Alpha Biz= Reporter Kim Jisun] Hanmi Pharmaceutical will continue under the leadership of current CEO Jae-Hyun Park after the board rejected a proposal to appoint Im Jong-yoon, the eldest son of the group’s founder, as the new CEO.
On September 2, the board of directors convened at Hanmi Pharmaceutical’s headquarters in Bangi-dong, Songpa-gu, Seoul, to discuss the nomination of Executive Director Im Jong-yoon as the new CEO. However, the proposal was voted down. Additionally, a proposal to replace the chairman of Beijing Hanmi Pharmaceutical and appoint new directors, which was also suggested by Im, was rejected. All ten board members, including CEO Park and Director Im, were present at the meeting.
With CEO Park retaining his position, Hanmi Pharmaceutical is set to continue its independent management strategy. Last month, Park established new HR and legal teams within Hanmi Pharmaceutical, emphasizing that the company would operate independently from its parent company, Hanmi Science.
Hanmi Pharmaceutical plans to gradually establish additional departments necessary for its independent management moving forward.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
